By Hendra Lukman 
An unprecedented examination of health records from Wales has provided some of the most compelling evidence to date suggesting that the shingles vaccine may offer a protective shield against dementia. A new study, spearheaded by researchers at Stanford Medicine, meticulously analyzed data from older adults, revealing that individuals who received the shingles vaccine were 20% less likely to be diagnosed with dementia over a subsequent seven-year period compared to their unvaccinated counterparts.
This groundbreaking research, published in the prestigious journal Nature on April 2, bolsters a burgeoning hypothesis within the scientific community: that certain viral infections, particularly those that impact the nervous system, could elevate the risk of developing dementia. Should these findings be substantiated by further investigation, they portend a readily accessible and practical strategy for dementia prevention.
The study’s impact is amplified by a second analysis from the same team, published in Cell on December 2. This subsequent research explored another significant potential benefit of the vaccine, suggesting it might also play a role in managing existing dementia, potentially slowing the rate at which the condition deteriorates.
The Shingles Virus: A Lifelong Companion
Shingles, a painful and blistering viral illness, is caused by the varicella-zoster virus (VZV), the same pathogen responsible for chickenpox. Once an individual contracts chickenpox, typically in childhood, the virus doesn’t entirely leave the body. Instead, it lies dormant within nerve cells, capable of reactivating years later. This reactivation, often triggered by age, a weakened immune system, or stress, manifests as shingles. The widespread prevalence of chickenpox means that a significant portion of the population carries the dormant VZV.
Dementia’s Growing Burden and the Viral Hypothesis
Globally, dementia affects over 55 million people, with approximately 10 million new cases diagnosed annually. For decades, the primary focus of dementia research has been on the accumulation of abnormal proteins in the brain, such as amyloid plaques and tau tangles, hallmarks of Alzheimer’s disease, the most common form of dementia. However, despite extensive efforts, these approaches have yet to yield effective preventive or curative treatments. This lack of progress has prompted a shift in attention towards other potential contributing factors, including the role of viral infections in causing long-term brain damage.
Prior observational studies, relying on existing health records, had hinted at a correlation between shingles vaccination and a reduced risk of dementia. However, these studies were hampered by a significant limitation: a confounding factor known as "healthy user bias." Individuals who opt for vaccination are often more health-conscious across a spectrum of behaviors – they may adhere to healthier diets, engage in regular exercise, and utilize healthcare services more frequently. These lifestyle differences, which are known to influence dementia risk, are not typically captured in medical databases, making it difficult to isolate the vaccine’s true effect.
Dr. Pascal Geldsetzer, an assistant professor of medicine and senior author of the new study, articulated this challenge: "All these associational studies suffer from the basic problem that people who go get vaccinated have different health behaviors than those who don’t. In general, they’re seen as not being solid enough evidence to make any recommendations on."
A "Natural Experiment" in Wales: Unraveling Bias
Approximately two years ago, Dr. Geldsetzer identified a unique opportunity within the way Wales implemented its shingles vaccination program. The program’s structure created what researchers term a "natural experiment," effectively mitigating the inherent biases present in earlier observational studies. At the time of the program’s inception, Wales utilized a live-attenuated shingles vaccine, meaning it contained a weakened form of the VZV.
The national vaccination initiative commenced on September 1, 2013. Under the policy, individuals who were precisely 79 years old on that specific date became eligible for the vaccine during the subsequent year. Those who turned 78 would become eligible the following year for a one-year window, and so forth. Crucially, individuals who had already reached their 80th birthday on September 1, 2013, were deemed ineligible and would never have the opportunity to receive the vaccine through this program.
This age-based eligibility criterion, determined by a fixed cut-off date, created a sharp demarcation in who could access the vaccine. This allowed researchers to conduct a powerful comparison between individuals who turned 80 just before the September 1, 2013 deadline and those who turned 80 just after. By comparing these two groups, scientists could meticulously assess the impact of vaccine eligibility on long-term health outcomes. Dr. Geldsetzer noted that the comprehensive health records available in Wales rendered this scenario remarkably akin to a randomized controlled trial, despite not being one in practice.
Comparing Near Identical Cohorts for Unbiased Insights
To leverage this fortuitous circumstance, the research team delved into the health records of over 280,000 older adults, aged between 71 and 88, who did not have a dementia diagnosis at the program’s outset. Their analysis then zeroed in on individuals whose birthdays placed them on either side of the eligibility line. Specifically, they compared those who turned 80 in the week preceding September 1, 2013, with those who celebrated their 80th birthday in the week following this crucial date.
"We know that if you take a thousand people at random born in one week and a thousand people at random, born a week later, there shouldn’t be anything different about them on average," Dr. Geldsetzer explained. "They are similar to each other apart from this tiny difference in age." The researchers operated under the assumption that a similar proportion of individuals in both groups would have desired the shingles vaccine. The pivotal distinction, however, was that only the slightly younger cohort – those not yet 80 on September 1, 2013 – were permitted to receive it under the established policy.
"What makes the study so powerful is that it’s essentially like a randomized trial with a control group — those a little bit too old to be eligible for the vaccine — and an intervention group — those just young enough to be eligible," Dr. Geldsetzer elaborated.
Quantifying Protection: Shingles and Dementia Rates
The research team meticulously tracked the health outcomes of these carefully selected individuals for the ensuing seven years, comparing those who were eligible for the vaccine with those who were not. By integrating this data with actual vaccination rates, they were able to estimate the protective effect of receiving the shot. The data indicated that approximately half of the eligible individuals ultimately received the vaccination, while virtually none of those deemed ineligible obtained it.
As anticipated, the vaccine demonstrated a significant impact on shingles incidence, reducing its occurrence by approximately 37% among vaccinated individuals over the seven-year follow-up period. This figure aligns with findings from clinical trials, acknowledging that the effectiveness of the live-attenuated vaccine can diminish over time.
By 2020, when the study participants were approaching their late eighties, roughly one in eight had developed dementia. However, within the group that received the shingles vaccine, the likelihood of receiving a dementia diagnosis was notably 20% lower when contrasted with those who remained unvaccinated. "It was a really striking finding," Dr. Geldsetzer remarked. "This huge protective signal was there, any which way you looked at the data."
Eliminating Alternative Explanations: Robust Findings
The researchers undertook a rigorous examination to rule out other potential factors that could account for the observed disparity in dementia rates. They discovered that the two comparison groups were remarkably similar across a wide range of measurable characteristics. Educational attainment levels were identical between eligible and ineligible individuals. Those who were eligible for the shingles vaccine were not more likely to receive other vaccinations or preventive therapies, nor were they less likely to suffer from common chronic illnesses such as diabetes, heart disease, or cancer. The only discernible and consistent difference between the groups was the reduced incidence of dementia diagnoses among those who had access to and received the shingles vaccine.
"Because of the unique way in which the vaccine was rolled out, bias in the analysis is much less likely than would usually be the case," Dr. Geldsetzer asserted, underscoring the strength of the study’s design.
Even with these robust findings, the team subjected their data to a variety of alternative analytical approaches. This included examining different age windows and focusing solely on mortality data where dementia was listed as a cause of death. Across all these varied analyses, the consistent relationship between shingles vaccination and a reduced risk of dementia persisted. "The signal in our data was so strong, so clear and so persistent," he emphasized.
Broader Therapeutic Potential: From Early Decline to Advanced Stages
The researchers then broadened their inquiry to investigate whether the vaccine’s apparent benefits extended beyond dementia prevention to individuals already exhibiting signs of cognitive decline. Employing the same natural experiment framework, they examined a wider spectrum of outcomes, encompassing mild cognitive impairment to advanced stages of dementia.
Many dementia diagnoses are preceded by a period of mild cognitive impairment (MCI), characterized by subtle deficits in memory and cognitive abilities that do not yet impede independent living, as explained by Dr. Geldsetzer. The study observed that individuals who had received the shingles vaccine were less likely to receive an MCI diagnosis during a nine-year follow-up period compared to their unvaccinated peers.
Furthermore, the research team turned their attention to individuals who already had dementia at the commencement of the Welsh vaccination program. The findings in this group were particularly striking. Individuals diagnosed with dementia who received the shingles vaccine exhibited a significantly lower likelihood of dying from dementia within the subsequent nine years, as indicated on their death certificates, compared to those who did not receive the vaccine. This suggests that the disease may have progressed at a slower pace in the vaccinated individuals.
Collectively, nearly half of the 7,049 Welsh seniors who had dementia when the program began died from dementia during the follow-up period. However, among those with dementia who received the shingles vaccine, only approximately 30% died from the condition. "The most exciting part is that this really suggests the shingles vaccine doesn’t have only preventive, delaying benefits for dementia, but also therapeutic potential for those who already have dementia," Dr. Geldsetzer stated, highlighting the profound implications of these findings.
Sex-Specific Effects and Unanswered Questions
A notable pattern emerged when the researchers analyzed outcomes by sex. The protective effect of the shingles vaccine against dementia appeared to be considerably more pronounced in women than in men. Dr. Geldsetzer posited that this disparity might reflect underlying biological differences in immune responses or variations in how dementia manifests in men and women. On average, women tend to mount higher antibody responses following vaccination, and shingles itself occurs more frequently in women.
The precise biological mechanisms by which the vaccine might be conferring protection remain an area of active investigation. It is currently unclear whether the effect is due to a broad stimulation of the immune system, a reduction in the reactivation frequency of the varicella-zoster virus, or an entirely different pathway.
Additionally, the potential impact of newer shingles vaccines, which utilize specific viral proteins and exhibit higher efficacy in preventing shingles, on dementia risk remains unknown. Whether these newer formulations offer similar or even enhanced protection against dementia requires further study.
Global Data and the Imperative for Randomized Trials
Dr. Geldsetzer expressed optimism that these findings will galvanize increased investment in this critical area of research. "At least investing a subset of our resources into investigating these pathways could lead to breakthroughs in terms of treatment and prevention," he urged.
Over the past two years, his team has expanded their analysis to include health records from other countries, such as England, Australia, New Zealand, and Canada, where similar shingles vaccine rollout programs were implemented. The results from these international datasets have consistently mirrored the observations made in Wales. "We just keep seeing this strong protective signal for dementia in dataset after dataset," he reported.
The paramount next step, according to Dr. Geldsetzer, is the initiation of a large-scale randomized controlled trial (RCT). Such a trial would provide the most rigorous scientific evidence to definitively establish whether the vaccine actively causes the observed reduction in dementia risk. In an RCT, participants would be randomly assigned to receive either the live-attenuated shingles vaccine or a placebo injection.
"It would be a very simple, pragmatic trial because we have a one-off intervention that we know is safe," Dr. Geldsetzer commented. He is actively seeking philanthropic support to fund this crucial endeavor, particularly as the live-attenuated vaccine, for which substantial evidence has been gathered from natural experiments, is now off-patent.
He also pointed out that such a trial could yield meaningful results relatively swiftly. In the Welsh data, the divergence in dementia rates between the eligible and ineligible groups began to manifest after approximately eighteen months.
This significant research was a collaborative effort, with contributions from a researcher at the Vienna University of Economics and Business. Funding for the study was provided by The Phil & Penny Knight Initiative for Brain Resilience, the Stanford Center for Digital Health, the National Institute on Aging (grant R01AG084535), the National Institute of Allergy and Infectious Diseases (grant DP2AI171011), and the Biohub in San Francisco.
